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ABSTRACT
The aim of the study was to analyse protective effects of different doses of pomiferin in therapy of reperfusion injury. Rats were 
randomly divided into five groups (n=10). One group was intact. Three medicated groups and one placebo group were subjected to 
ischaemia and reperfusion of the left kidney. Pomiferin was administrated by single gastric gavage in 2 ml of 0.5% Avicel solution in 
doses of 5, 10 and 20 mg/kg. The placebo group was given only Avicel solution. On day 15, all the animals were exsanguinated and the 
reperfused kidneys were recovered. Selected biochemical markers were assessed in blood: antioxidative enzymes, total antioxidative 
capacity, malondialdehyde, creatinine, urea and uric acid. Creatinine, urea and total proteins were analysed in urine and 24-hour 
diuresis was recorded. The kidney tissue samples were used for histopathological examination.
The results confirmed the expected protective effects of pomiferin. Pomiferin supported defensive reactions of the body against free 
radicals (increased levels of superoxide dismutase, total antioxidative capacity), decreased lipid peroxidation (decreased malondialde-
hyde) and contributed to the recovery of kidney functions (creatinine and urea in blood). The best biochemical and histopathological 
results were achieved after pomiferin administration in the dose of 5 mg/kg. 
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and permeability, fragmentation or random cross linking 
of molecules like DNA, enzymes and structural proteins 
(Carattino et al., 1999; Ratnam et al., 2006). 
Ischaemia and hypoxia have many biological effects, 
including depletion of ATP, increased levels of calcium, 
and alteration in membrane lipids and enzyme activities 
(Tamura et al., 1996). Xanthine dehydrogenase is con-
verted to xanthine oxidase (XOD) during ischaemia. In 
reperfusion – reoxygenation of ischaemic tissue – XOD 
becomes the main source of ROS. Cytochrome c and 
apoptosis-inducing factor are released into the cytoplasm 
(Zhao, 2004). Production of ROS is very fast – in the isch-
aemic myocardium ROS are detected in the first minutes 
after reperfusion (Zhao, 2004). ROS attack cells, induce 
synthesis of adhesive molecules which attract neutrophils 
– producers of other ROS molecules (Drabikova et al., 
2002). All these actions cause oxidative injury. 
ROS play an important role in the pathogenesis of 
ischaemia-reperfusion (I/R) injury in the kidney (Serteser 
et al., 2002; Singh & Chopra, 2004). Renal ischaemia is an 
important clinical problem in renal transplantation, in the 
Introduction
Reactive oxygen or nitrogen species (ROS/RNS) are 
constantly formed in the organism during physiological 
processes or they are derived from external sources and 
eliminated by the antioxidant defence of the organism 
(Yu, 1994). There are many sources of free radicals in the 
metabolic pathways: respiration chain in mitochondria, 
metabolism of catecholamines and prostanoids, xanthine 
oxidase, NAD(P)H-oxidase, and several other enzymatic 
systems. Under physiological conditions, a balance exists 
between the level of ROS and the level of endogenous anti-
oxidants. When this balance is disrupted, oxidative stress 
occurs. ROS modify cell membrane lipids, proteins and 
nucleic acids, leading to changes in membrane fluidity 
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early allograft rejection subsequent to renal transplanta-
tion, cardiovascular surgery, etc. I/R injury can result in 
acute renal failure. Acute renal failure is a clinical and 
experimental syndrome characterised by major reduction 
in glomerular filtration rate, extensive tubular damage, 
tubular cell necrosis, glomerular injury, and signs of tubu-
lar obstruction with cell debris (Singh & Chopra, 2004).
Therapy of ischaemic injury is complicated. The use of 
preventive approaches – strengthening of natural antioxi-
dative mechanisms – has proved effective (Janostikova et 
al., 2005; Pecivova et al., 2004). If this is not possible, I/R 
injury has to be reduced by therapeutic administration of 
compounds which act as free radical scavengers.
Flavonoids are a heterogeneous group of phenol com-
pounds. In human diet, the most abundant of them are 
polyphenols. Many positive and also negative effects of 
flavonoids have been described (Van Hoorn et al., 2002).
Depending on their chemical structure, flavonoids 
can act as antioxidants and scavengers via several 
mechanisms (Shon et al., 2004). Flavonoids have their 
own antioxidative capacity and they are able to regulate 
enzymes such as xanthine oxidase, phospholipase and 
nitric oxide synthase. They can inhibit peroxynitrite in 
activated macrophages (Van Hoorn et al., 2002).
Pomiferin 3-(3,4-dihydroxy-phenyl)-5-hydroxy-8,8-
dimethyl-6-(3-methyl-but-2-enyl)-8H-pyrano[2,3-f]chro-
men-4-one (Figure 1) belongs to the group of prenylated 
isoflavones. The compound was isolated from Maclura 
pomifera (Raf.) Schneid. (Moraceae) and its purity was 
HPLC-proved (Janostikova et al., 2005). 
The aim of the study was to analyse the effects of 
different doses of pomiferin administered during the 
therapy of ischaemia-reperfusion injury of kidney tissue 
in laboratory rats.
The study and its experimental protocol were 
approved and monitored by the Ethical Committee 
of the University of Veterinary and Pharmaceutical 
Sciences Brno. The experiment was performed by the 
work group whose members are holders of the Certificate 
on Professional Competence issued by the Central 
Commission for Animal Protection pursuant to §17 of 
the Act on Protection of Animals against Cruelty (No. 
246/1992 Coll.) of the Czech National Council. 
Materials and methods
Male Wistar SPF laboratory rats (origin – AnLab, 
Germany) were used in the study. All animals were of the 
same age and comparable weight (250 ± 10 g). They were 
housed in a room with standard temperature and light 
regime, fed a standard diet (Complete diet for laboratory 
mice and rats in SPF breedings – M1; origin – Ing. F. 
Nachal, VKS Jirikov, Czech Republic, Reg. No. 10250) and 
received water ad libitum. 
A f t e r  1 0  d a y s  o f  a c c l i m a t i o n ,  5 0  a n i m a l s  w e r e  
randomised in 5 groups (n=10). One group was left 
intact. Four groups underwent laparotomy in general 
anaesthesia (2% Rometar (xylazine) 0.5 ml + Narkamon 
(ketamine) 10  ml, dose 0.5  ml solution /100  g of body 
mass). Ischaemia-reperfusion injury was induced by 
applying a vascular clamp on the left renal artery for 
60 min with subsequent renal reperfusion. Each animal 
(including those of the intact group) was put into its own 
metabolic cage. For 15 days all the animals were bred in 
these cages. The doses of pomiferin were suspended in 
2 ml of 0.5% Avicel solution (microcrystalline cellulose) 
and were administered starting with day 1 after opera-
tion. Three of four operated groups were medicated with 
pomiferin – orally by gastric gavage once a day in differ-
ent doses: 5 mg/kg, 10 mg/kg and 20 mg/kg. The placebo 
group was given 2 ml of 0.5% Avicel by the same route. 
On day 15, all the animals were exsanguinated in general 
anaesthesia (2% Rometar 0.5 ml + Narkamon 10 ml, dose 
0.5 ml solution /100 g of the rat body mass) by blood col-
lection from the left ventricle and the reperfused kidney 
tissue was employed for histopathological examination. 
Selected biochemical markers were assessed in 
blood: superoxide dismutase (SOD, EC 1.15.1.1) (Arthur 
and Boyne, 1993), glutathione peroxidase (GSHpx, EC 
1.11.1.9) (Paglia and Valentine, 1967), total antioxidative 
capacity (AOC) (Miller et al., 1993) using RANDOX test-
ing kits (Dublin, Ireland), in COBAS MIRA S automatic 
analyser, and malondialdehyde (MDA) was analysed 
spectrophotometrically using the TBARs method (Kosugi 
and Kikugawa, 1989); creatinine, urea and uric acid 
were assessed in blood by standard laboratory methods 
using BIO-LA-TEST testing kits (Pliva-Lachema, Czech 
Republic). Creatinine, urea and total protein were anal-
ysed in urine by standard laboratory methods using BIO-
LA-TEST testing kits (Pliva-Lachema, Czech Republic). 
Diuresis/24 hours was measured using a calibrated glass 
container. 
The kidney tissue samples were fixed in 10% formal-
dehyde and processed manually. Two blocks were made 
of each sample, the sections were stained with haema-
toxylin-eosin. All evaluated samples were of outstanding 
quality. The evaluation was performed by a histopatholo-
gist without knowledge of the experimental protocol. 
E v al u a ti o n  p r in c i p l e :  e a c h  s am p l e  o f  th e  m a t e r i al  
was evaluated and scored separately in 3 kidney tissue 
structures, the results were added up and in the end the 
average score of each medicated group was stated.
O O
O
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OH
Pomiferin
C25H24O6
Mr 420.46
Figure 1. Chemical structure of pomiferin.78
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Scoring schedule
1st tissue structure – kidney medulla – the grade of tissue 
destruction through bleeding (according to the extent) 
and presence of inflammatory infiltrate were evaluated, 
indicated as plus (+) sign (max. 3+) 
2nd tissue structure – cortex and glomerules – both 
extraglomerular (max. 1+) presence of haemorrhages and 
increased cellularity and extravasates in the glomerule 
(max. 2++) were evaluated.
3rd tissue structure – kidney tubules – presence of 
regressive changes of epithelia from edema to necrosis 
were evaluated (+ in the case of necrosis and ± in the 
case of regression not reaching the grade of necrosis). In 
addition, the tubule content was evaluated (protein and 
hyaline cylinders +). Maximum 2++.
The most extensive damage – the highest possible 
score per one sample was 7.
Statistical analysis
The results were processed by the Microsoft® Excel® table 
processor and statistically interpreted using Unistat 
programme and ANOVA test. The value p≤0.05 was 
considered significant.
Results
All the results were obtained from samples (blood, urine, 
kidney tissue) of the 15th day of the experiment. 
Results of biochemical examination
Biochemical results are given in Tables 1–3. A statistically 
highly significant increase of SOD activities (p≤0.01) was 
detected in the groups medicated with the doses of 5, 10, 
and 20 mg/kg, compared with the placebo and the intact 
group. Mutual comparison of the SOD activities among 
the groups medicated with different doses of pomiferin 
did not show significant differences and the difference 
between the placebo and the intact group was statistically 
nonsignificant. 
GSHPx activities in all medicated groups were signifi-
cantly decreased (p≤0.01), compared with the placebo and 
the intact group. Comparison of GSHPx activities ascer-
tained in the groups medicated with doses of 5 and 10 mg/
kg showed a significant difference (p≤0.01), as did the com-
parison between the groups medicated with doses of 10 and 
20 mg/kg (p≤0.05). GSHPx activity in the placebo group 
was decreased (p≤0.01) compared with the intact group.
A significant increase of AOC values (p≤0.01) was 
detected in all groups medicated with pomiferin, compared 
with the placebo and the intact group but mutual compari-
son among all medicated groups as well as between the 
placebo and the intact group were nonsignificant. 
The MDA concentrations in blood were significantly 
(p≤0.01) decreased in all medicated groups compared 
with the placebo group. Compared with the intact 
group, MDA concentration was decreased in the group 
medicated with the doses of 5 mg/kg and increased in the 
groups medicated with pomiferin in the doses of 10 and 
20 mg/kg. Comparison of the concentrations ascertained 
in the placebo and intact group showed an increase 
(p≤0.01) of MDA concentration in the placebo group.
The creatinine concentration was significantly 
decreased (p≤0.01) in the group medicated with the dose 
of 20  mg/kg, compared with the placebo and the intact 
group. A significantly increased concentraion of creati-
nine (p≤0.05) was detected in the group medicated with 
the dose of 10  mg/kg, compared with the intact group. 
In the placebo group, the creatinine concentration was 
significantly increased (p≤0.01) compared with the intact 
group. The creatinine concentration closest to the level 
of the intact group was detected in the group medicated 
with pomiferin in the dose of 5 mg/kg. In the mutual com-
parison, significant differences were recorded between 
the groups medicated with the doses of 5 and 20 mg/kg 
(p≤0.05) and between the groups medicated with the 
doses of 10 and 20 mg/kg (p≤0.01). The creatinine con-
centration was increased (p≤0.01) in the placebo group, 
compared with the intact group.
The urea concentrations were increased (p≤0.01) in 
the group medicated with the dose of 10 mg/kg and the 
placebo group, compared with the intact group. The urea 
concentration closest to the level of the intact group was 
detected in the group treated with the dose of 5 mg/kg. 
Mutual comparison of the urea concentrations among 
the groups medicated with different doses of pomiferin 
did not show significant differences. Comparison of the 
values obtained in the placebo group and the intact group 
showed an increase (p≤0.01) of urea concentration in the 
placebo group.
The concentration of uric acid was increased (p≤0.05) 
in the group medicated with the dose of 20 mg/kg, com-
pared with the placebo and the intact group. The uric acid 
value closest to the concentration of the intact group was 
detected in the group medicated with the dose of 10 mg/
kg. Comparison of uric acid concentrations obtained in 
the groups medicated with pomiferin in doses of 5 and 
10  mg/kg, 5 and 20  mg/kg, and 10 and 20  mg/kgshowed 
significant differences (p≤0.05). Mutual comparison of 
uric acid concentrations in all medicated groups showed 
significant differences (p≤0.05). There was no significant 
difference between the placebo and intact animal group. 
A significant increase of creatinine concentration 
(p≤0.05) was detected in all groups medicated with 
pomiferin, compared with the intact group and a decrease 
(p≤0.05) in the groups medicated with the dose of 5 and 
20  mg/kg, compared with the placebo group. The cre-
atinine concentration closest to the concentration of the 
intact group was detected in the group medicated with 
the dose of 5  mg/kg. Mutual comparison of creatinine 
concentrations in all medicated groups did not show 
significant differences. The creatinine concentration was 
increased (p≤0.01) in the placebo group, compared with 
the intact group. 
Urea concentrations were increased (p≤0.01and 
p≤0.05) in the groups medicated with the respective 
doses of 5 and 20 mg/kg and 5 and 10 mg/kg, compared 
with the intact group. The urea concentration closest to 79
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Table 1. Biochemical markers of I/R injury assessed in blood, expressed as X ± SD.
Group of animals (n=10)
SOD 
(U/ml)
GSHPx 
(μkat/L)
AOC 
(mmol/L)
MDA 
(mmol/L)
Medicated groups 
Dose of pomiferin
5 mg/kg 234.45 ± 3.54 
** ++
1036.58 ± 52.28
** ++
0.57 ± 0.02
** ++
0.40 ± 0.30
** ++
10 mg/kg 240.03 ± 17.56 
** ++
1138.50 ± 67.28
** ++
0.53 ± 0.07
** ++
4.11 ± 1.42
** ++
20 mg/kg 234.54 ± 16.79 
** ++
1064.75 ± 53.25
** ++
0.58 ± 0.05
** ++
4.23 ± 1.11
** ++
Placebo group 70.39 ± 2.79 1329.00 ± 91.41
‡‡ 0.41 ± 0.04 17.17 ± 1.12
‡‡
Intact group 67.37 ± 3.97 1509.38 ± 147.93 0.43 ± 0.03 1.89 ± 0.16
* p≤0.05 treated vs placebo group; ** p≤0.01 tretaed vs placebo group
+ p≤0.05 treated vs intact group; ++ p≤0.01 treated vs intact group
‡ p≤0.05 placebo vs intact group; ‡‡ p≤0.01 placebo vs intact group
Table 2. Biochemical markers of kidney function assessed in blood, expressed as X ± SD
Group of animals 
(n=10)
Creatinine 
(μmol/ml)
Urea 
(mmol/L)
Uric Acid 
(μmol/ml)
Medicated groups 
Dose of pomiferin
5 mg/kg 43.43 ± 4.72 6.57 ± 1.51
+
22.05 ± 6.82
10 mg/kg 44.60 ± 1.95
+
7.61 ± 1.04
++
16.00 ± 3.36
20 mg/kg 37.91 ± 2.50
** ++
6.72 ± 1.00 34.45 ± 15.71
* +
Placebo group 44.83 ± 1.78
‡‡
7.21 ± 0.56
‡‡
18.91 ± 5.64
Intact group 42.00 ± 1.94 6.35 ± 0.25 18.68 ± 4.00
* p≤0.05 treated vs placebo group; ** p≤0.01 tretaed vs placebo group
+ p≤0.05 treated vs intact group; ++ p≤0.01 treated vs intact group
‡ p≤0.05 placebo vs intact group; ‡‡ p≤0.01 placebo vs intact group
Table 3. Biochemical markers of kidney function assessed in urine, expressed as X ± SD
Group of animals (n=10)
Creatinine 
(μmol/ml)
Urea
(mmol/L)
Total Protein
(g/L)
Diuresis/24 h
(ml)
Medicated groups 
Dose of pomiferin
5 mg/kg 1731.45 ± 433.95
* +
289.23 ± 73.07
++
1.16 ± 0.21
* ++
25.75 ± 5.47
++
10 mg/kg 2232.60 ± 960.90
+
378.33 ± 219.60
+
1.34 ± 0.36
* ++
28.89 ± 12.10
++
20 mg/kg 1795.35 ± 492.93
* +
322.73 ± 129.18
++
1.36 ± 0.35
** ++
31.19 ± 9.11
* ++
Placebo group 3245.90 ± 1392.93
‡‡
426.01 ± 241.78
‡
0.83 ± 0.37
‡
19.63 ± 10.75
‡‡
Intact group 1152.21 ± 453.88 143.88 ± 67.25 0.43 ± 0.16 50.16 ± 10.44
* p≤0.05 treated vs placebo group; ** p≤0.01 tretaed vs placebo group
+ p≤0.05 treated vs intact group; ++ p≤0.01 treated vs intact group
‡ p≤0.05 placebo vs intact group; ‡‡ p≤0.01 placebo vs intact group
the concentration of the intact group was detected in the 
group medicated with the dose of 5 mg/kg. Mutual com-
parisons of urea concentrations obtained in all medicated 
groups were nonsignificant. The urea concentration was 
increased (p≤0.05) in the placebo group, compared with 
the intact group. 
The total protein concentration was increased (p≤0.01) 
in all medicated groups, compared with the intact 
group. The total protein concentration was increased in 
the groups medicated with the dose of 5 and 10  mg/kg 
(p≤0.05) and in the group medicated with the dose of 
20 mg/kg (p≤0.01), compared with the placebo group. The 
total protein concentration closest to the concentration 
of the intact group was detected in the group medicated 
with the dose of 5  mg/kg. Mutual comparisons of total 
protein concentrations recorded in all medicated groups 80
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were nonsignificant. The total protein concentration was 
increased (p≤0.05) in the placebo group, compared with 
the intact group. 
A significant decrease of daily diuresis (p≤0.01) was 
detected in all groups medicated with pomiferin and in 
the placebo group, compared with the intact group. The 
daily diuresis closest to the value of the intact group 
was detected in the group medicated with the dose of 
20 mg/kg. Mutual comparisons of daily diuresis as mea-
sured in all medicated groups were nonsignificant. The 
daily diuresis value in the placebo group was decreased 
(p≤0.01), compared with the intact group. 
Results of histopathological examination
The medicated groups: 
The optimal protective effect appeared after administra-
tion of pomiferin in the dose of 5  mg/kg. The average 
score of the samples of this group was 3.3. In the 1st tissue 
structure (kidney medulla) the best result was achieved 
after administration of the highest dose of pomiferin – 
20 mg/kg, the average score of this tissue structure being 
1.0. In all medicated groups, the average presence of the 
inflammation was 88%.
The placebo group: 
Typical ischaemic changes were observed in all samples. 
The score was oscillating from 2.0 to 5.5 with the aver-
age of 4.3. Inflammatory infiltrate was found rather 
frequently along with the presence of polymorphonuclear 
neutrophils (67%). 
The intact control group: 
Haemorrhage occurred only accidentally, most probably 
caused by contusion.
DISCUSSION
The prenylated isoflavonoid pomiferin is a substance 
which was only rarely tested in vivo (Janostikova et al., 
2005; Florian et al., 2006). Its antioxidative effect may be 
achieved by several mechanisms. According to its struc-
ture, it could chelate copper and iron, which are potential 
inducers of Fenton reaction and it could also inactivate 
xanthine oxidase (Ratnam et al., 2006). Generally, flavo-
noids are able to inactivate hydrogen peroxide, peroxyl 
radicals, and thus protect lipids against peroxidation, 
inhibit activation of phospholipase A2 and degradation of 
arachidonic acid in lipid membranes (Bors et al., 1990).
Our study analysed the relation between the thera-
peutic effect and the dose of pomiferin used under the 
conditions of kidney ischaemia-reperfusion in the labora-
tory rat. 
The statistically significant higher SOD activities 
found in the medicated groups confirmed the readiness 
of the organism to destroy superoxide. In our study, the 
activity of SOD in the treated groups was approximately 
three times higher than in the intact group. In a similar 
type of study (Singh and Chopra, 2004) the tested fla-
vonoid naringin decreased the activity of SOD to 50% 
compared to sham control. There was no linear relation 
between the dose of pomiferin and the activity of SOD in 
our study. The highest effect on SOD activity increase was 
found with the middle dose – 10 mg/kg.
Statistically significant was the decrease of GSHPx 
activities in all medicated groups. With the middle dose – 
10 mg/kg – the GSHPx activity was the highest. 
Since the analysed enzymes are intracellular and 
their activities follow one another, we can suppose that 
their concentrations are influenced by the type of ROS 
that is actually present. The massive production of SOD 
may have been a physiological response, supported by the 
effect of pomiferin, to the presence of the huge amount of 
superoxide, whereas GSHPx did not have hydrogen per-
oxide enough at the moment of assessment, and thus its 
activities were not increased yet. Pomiferin could also co-
operate in scavenging actions and this way influence the 
level of irritating type of ROS. The detailed mechanisms 
of these supposed actions are unknown. The views on 
changes of SOD and GSHPx activities caused by declining 
kidney function are inconsistent – some authors suggest 
increased activities (Chen et al., 1996), others decreased 
(Racek et al., 1995, Singh & Chopra, 2004), or unaffected 
activities (Durackova, 1997). 
AOC is not the most specific determinant of antioxida-
tive abilities of the organism because it is a sum of effects 
of many antioxidative factors. Uric acid, which is the final 
product of degradation of AMP, is a very important anti-
oxidant in blood. In our study, uric acid was significantly 
Table 4. Final scoring for all treated groups.
Group of animals
(n=10) SOD GSHPx AOC MDA
in blood in urine
Diuresis/
24 h
Histopa-
thology
Final 
evaluation Creatinine Urea Uric acid  Creatinine Urea
Total 
protein
Dose of 
pomiferin
5 mg/kg ••• ••• • 7
10 mg/kg •• • 3
20 mg/kg •• 2
• indicates the best result for each evaluated parameter or biochemical marker81
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(p≤0.05) increased only in one case – after the admin-
istration of pomiferin in the dose of 20 mg/kg, whereas 
AOC was significantly increased (p≤0.01) in all medicated 
groups. Flavonoids or other compounds with potential 
antioxidative effect usually increase AOC (Toborek et al., 
1992; Jackson et al., 1995).
MDA is a toxic byproduct of lipoperoxidation and its 
concentration usually correlates with the intensity of ROS 
action in lipid membranes and thus also with the severity 
of oxidative injury. Increased concentration of MDA may 
be caused by decreased renal elimination during renal 
failure (Racek et al., 1997). Although the TBARs method 
(Kosugi & Kikugawa, 1989) with spectrophotometrical 
assessment is not the most specific one, it is sufficient for 
our measurements, because it is the difference between 
the assessed concentrations in medicated groups and 
the placebo or intact group that is important, not the 
exact quantity of TBARs products. A statistically highly 
significant decrease of MDA concentrations was recorded 
in all medicated groups in our study. This result correlates 
with the assumption of inhibition of lipoperoxidation by 
flavonoids – in our case pomiferin. The best result was 
achieved after administration of the lowest dose of pomif-
erin – 5 mg/kg. This value was even lower than the level of 
MDA in the intact group.
Acute renal failure was evident particularly in the 
placebo group. Elevated levels of creatinine and urea in 
blood and urine along with reduction of daily diuresis are 
results of homeostatic imbalance caused by renal failure. 
After fifteen days of pomiferin medication, biochemical 
markers reached practically physiological levels. In the 
medicated groups, the positive influence of pomiferin was 
manifested in daily diuresis, which was higher than in the 
placebo group. 
Histopathological results allow to describe the mea-
sure of damage quite exactly. There were mostly inflam-
matory and necrotic changes it this type of experiment 
where the reperfusion after 60 minutes of ischaemia 
lasted 15 days. The placebo group with mostly massive 
ischaemic changes reached 4.3 points in average. The 
medicated groups achieved better results, the best one 
(3.3) was recorded after pomiferin administration in the 
dose of 5 mg/kg. 
Biochemical and histopathological results cor-
responded and confirmed the antioxidative capacity of 
pomiferin. The relation between the dose and the effect 
was linear only in few parameters (MDA, total protein and 
daily diuresis). The best results in biochemical parameters 
were reached by the group medicated with pomiferin in 
the dose of 5 mg/kgand the histopathological examination 
confirmed this dose as the most effective one. We can 
conclude that pomiferin medication supported strongly 
the physiological antioxidative system, contributed to the 
antioxidative capacity and thus reduced lipoperoxidation 
of lipids in cell membranes. By all these ways, pomiferin 
participated in the preservation of vitality of the filtration 
system in the kidney.
The results of this study can be used to advantage in 
further preclinical examinations of pomiferin. 
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